56 results
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
6 Jun 24
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
2:57pm
have increased our access to cash while keeping dilution to a minimum. We plan to continue this strategy, which has shown desired outcomes so far
8-K
EX-99.2
MAIA
MAIA Biotechnology Inc
4 Jun 24
Regulation FD Disclosure
4:06pm
security access our or related financial instrument or to participate in any trading strategy. The summary may include “forward-looking statements
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
4 Jun 24
Regulation FD Disclosure
4:06pm
capital expenditures and liquidity; changes in our strategy; government regulations and approvals; the application of certain service license … : Telomere targeting compounds (2034+) THIO’s immunogenic treatment strategy: sequential combination with CPIs (2041) 25
EXPERIENCED MANAGEMENT TEAM NYSE
424B5
1e8 jklq9
14 Feb 24
Prospectus supplement for primary offering
5:18pm
424B5
1wed3nzqknd2ltts2gr
17 Nov 23
Prospectus supplement for primary offering
9:06am
8-K
EX-99.1
4ycikyxtda0b0
13 Nov 23
Other Events
6:07am
8-K
EX-99.1
8vd81egw0s
28 Sep 23
MAIA Biotechnology Announces Share Repurchase Program
5:12pm
424B5
mepx 55sgxjhn
1 Sep 23
Prospectus supplement for primary offering
4:30pm
S-3
57jgv4n
14 Aug 23
Shelf registration
6:05pm
FWP
3vc1c9ez2d4e96 rig2n
11 Jul 23
Free writing prospectus
12:42pm
FWP
7qeou66
9 Jun 23
Free writing prospectus
6:47am
DRS
pkf7u336dnk0
1 Jun 23
Draft registration statement
12:00am
424B4
k3gunrv
25 Apr 23
Prospectus supplement with pricing info
7:45pm
FWP
qe6y8msy9 w4aog
20 Apr 23
Free writing prospectus
9:38am